The roles of P-gp in the development of drug-resistant phenotypes are indicated in NHL patients since P-gp inhibitors have been shown to be effective in patients harboring a drug-resistant phenotype [12,13,14]. The gene discussed is PGP; the disease is non-Hodgkin lymphoma.